GlaxoSmithKline gets lift from successful arthritis drug trials
Advertisement
London: GlaxoSmithKline reported positive results from three pivotal studies of its experimental rheumatoid arthritis drug sirukumab, putting the medicine on track to be submitted for regulatory approval in 2016.
Sirukumab, an anti-interleukin (IL)-6 antibody, was one of several near-term new drug opportunities highlighted by the British drugmaker last month during a research update for investors.
GlaxoSmithKline is developing the drug in collaboration with Johnson & Johnson. It is also being studied for treating patients with giant cell arteritis, a disorder causing inflammation of the arteries.
Existing IL-6 drugs include Roche's Actemra, which was approved for rheumatoid arthritis by the U.S. Food and Drug Administration in 2010.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.